ResearcherFirst Hospital of Jilin UniversityNo recent work listed

Zhuo Fu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6462-7695; OpenAlex author ID A5031036081. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2019: 2 papers

Papers 2

TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer. Co-author DOI 10.1097/md.0000000000018487 ↗
Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer. First author DOI 10.1371/journal.pone.0211291 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yan Jiao · 2 shared papers, 2019 · strength 0.24
- Paper Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer. DOI 10.1371/journal.pone.0211291 ↗
- Paper TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer. DOI 10.1097/md.0000000000018487 ↗
Yahui Liu · 1 shared paper, 2019 · strength 0.12
- Paper Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer. DOI 10.1371/journal.pone.0211291 ↗
Bin Liu · 1 shared paper, 2019 · strength 0.11
- Paper TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer. DOI 10.1097/md.0000000000018487 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.